<DOC>
	<DOCNO>NCT00357604</DOCNO>
	<brief_summary>The purpose study administer combine oral contraceptive ( ethinyl estradiol norgestimate ) HIV treatment atazanavir ritonavir healthy female order ass concentration oral contraceptive change . The safety treatment regimen also study .</brief_summary>
	<brief_title>Atazanavir Ritonavir ( ATV/RTV ) Oral Contraceptive Healthy Females</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Norgestimate</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Women childbearing potential intact ovarian function stable regimen oral contraceptive least 2 month prior begin study Documented acceptable Pap smear within 1 year prior dose Body mass index ( BMI ) 1832 kg/m2 Males Subjects abnormal menstrual cycle 2 month prior start study leadin period ( breakthrough bleeding/spotting ) History condition use oral contraceptive contraindicate Known suspect carcinoma suspect estrogen dependent neoplasia History migraine focal aura History uncontrolled hypertension Positive screen test HIV1 , 2 , HIV viral ribonucleic acid ( RNA ) , hepatitis B surface antigen , hepatitis C antibody</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>HIV</keyword>
	<keyword>Protease Inhibitor</keyword>
</DOC>